165 related articles for article (PubMed ID: 32778954)
1. Designing a new bispecific tandem single-chain variable fragment antibody against tumor necrosis factor-α and interleukin-23 using in silico studies for the treatment of rheumatoid arthritis.
Barkhordari A; Mahnam K; Mirmohammad-Sadeghi H
J Mol Model; 2020 Aug; 26(9):225. PubMed ID: 32778954
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis.
Kang SE; Park JK; Yoo HJ; Kang HS; Park YW; Park BC; Park JE; Lee EY; Lee EB; Song YW
Transl Res; 2021 Jun; 232():75-87. PubMed ID: 33453429
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G
Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306
[TBL] [Abstract][Full Text] [Related]
4. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
Zaka M; Abbasi BH; Durdagi S
J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
6. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
Zaka M; Abbasi BH; Durdagi S
J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
[TBL] [Abstract][Full Text] [Related]
7. [Construction and functional analysis of a bispecific antibody that targets TNF-α and ED-B].
Li LJ; Yang YQ; Hu XP; Xie M; Liu MY
Yao Xue Xue Bao; 2014 Dec; 49(12):1665-73. PubMed ID: 25920195
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific antibody targeting tumor necrosis factor α and ED-B fibronectin effectively inhibits the progression of established collagen-induce arthritis.
Liu M; Xie M; Jiang S; Liu G; Li L; Liu D; Yang X
J Biotechnol; 2014 Sep; 186():1-12. PubMed ID: 24992210
[TBL] [Abstract][Full Text] [Related]
9. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
10. Production of a bispecific antibody targeting TNF-α and C5a in Pichia pastoris and its therapeutic potential in rheumatoid arthritis.
Chen J; He Z; Fan Y; Zhou X; Li L; Liu M
Biotechnol Lett; 2020 Apr; 42(4):557-569. PubMed ID: 32040674
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis.
Qi J; Ye X; Ren G; Kan F; Zhang Y; Guo M; Zhang Z; Li D
Mol Immunol; 2014 Feb; 57(2):59-65. PubMed ID: 24091292
[TBL] [Abstract][Full Text] [Related]
12. Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis.
Ferrari M; Onuoha SC; Fossati-Jimack L; Nerviani A; Alves PL; Pagani S; Deantonio C; Colombo F; Santoro C; Sblattero D; Pitzalis C
Front Immunol; 2021; 12():640070. PubMed ID: 33679801
[TBL] [Abstract][Full Text] [Related]
13. Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A.
Zheng S; Shen F; Jones B; Fink D; Geist B; Nnane I; Zhou Z; Hall J; Malaviya R; Ort T; Wang W
MAbs; 2020; 12(1):1770018. PubMed ID: 32544369
[TBL] [Abstract][Full Text] [Related]
14. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
15. The recombinant anti-TNF-α fusion protein ameliorates rheumatoid arthritis by the protective role of autophagy.
Chen X; Nie K; Zhang X; Tan S; Zheng Q; Wang Y; Chen X; Tang Z; Liu R; Yan M; Liu Z; Lin J; Xu J; Zhang N; Wang H; Yang J
Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880389
[TBL] [Abstract][Full Text] [Related]
16. A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides.
Geng S; Chang H; Qin W; Lv M; Li Y; Feng J; Shen B
Immunol Res; 2015 Jul; 62(3):377-85. PubMed ID: 26059602
[TBL] [Abstract][Full Text] [Related]
17. A recombinant IgG-like bispecific antibody acting as interleukin-1β and interleukin-17A inhibitor exhibits a promising efficacy for rheumatoid arthritis.
Wang Y; Wu Q; Liu Z; Guo X; Zhou L; Wang Y; Song L; Wang N; Zheng Q; Wang W; Ren G; Li D
Biomed Pharmacother; 2017 May; 89():426-437. PubMed ID: 28249243
[TBL] [Abstract][Full Text] [Related]
18. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
19. Analysis of interleukin 23 and 7G10 interactions for computational design of lead antibodies against immune-mediated inflammatory diseases.
Saba Khan N; Verma R; Pradhan D; Nayek A; Bhuyan R; Kumar Sahu T; Kumar Jain A
J Recept Signal Transduct Res; 2018 Aug; 38(4):327-334. PubMed ID: 30481093
[TBL] [Abstract][Full Text] [Related]
20. T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites.
Yoshida S; Kobayashi T; Matsuoka H; Seki C; Gosnell WL; Chang SP; Ishii A
Blood; 2003 Mar; 101(6):2300-6. PubMed ID: 12411309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
